&nbsp;

CoP-Fall2023.pdf

Dec 2023

Document

CART-cellTherapyForAdultWithRelapsedRefractoryB-cellALL.pdf

Dec 2023

Document

CART-cellTherapyforPediatricRelapsedRefractoryB-cellALL.pdf

Dec 2023

Regimen

CARFDEXASELI

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

carfilzomib (Unfunded),

dexamethasone,

selinexor (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Mar 2024

Document

ConsolidatedMethodologyTechnicalAppendix.pdf

Jan 2024

Guidelines and Advice

Consensus Diagnostic and Prognostic Testing for Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: Recommendations Report - 2024

Status: Current
Version: 1.0

Jan 2024

Document

Cervical Postcard - French.pdf

Feb 2024

Document

CCO Clinical Trials Assessment

Mar 2024

Guidelines and Advice

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Status: Current
ID: C50-CIDAP-1

Mar 2024

Regimen

CRBPGEMC+DURV

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

CISPGEMC+DURV

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

AZCTGILTVENE

Intent: Curative, Palliative

Funding:

New Drug Funding Program

Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia

Drugs Used:

azaCITIDine,

venetoclax,

gilteritinib (Unfunded)

... Show more tags